Centralisation of specialist cancer surgery services in two areas of England: the RESPECT-21 mixed-methods evaluation

Author:

Fulop Naomi J1ORCID,Ramsay Angus IG1ORCID,Vindrola-Padros Cecilia1ORCID,Clarke Caroline S2ORCID,Hunter Rachael2ORCID,Black Georgia1ORCID,Wood Victoria J1ORCID,Melnychuk Mariya1ORCID,Perry Catherine3ORCID,Vallejo-Torres Laura4ORCID,Ng Pei Li1ORCID,Barod Ravi5,Bex Axel56,Boaden Ruth7ORCID,Bhuiya Afsana8ORCID,Brinton Veronica9ORCID,Fahy Patrick10ORCID,Hines John11ORCID,Levermore Claire12ORCID,Maddineni Satish13,Mughal Muntzer M8ORCID,Pritchard-Jones Kathy814ORCID,Sandell John9ORCID,Shackley David15ORCID,Tran Maxine56ORCID,Morris Steve16ORCID

Affiliation:

1. Department of Applied Health Research, University College London, London, UK

2. Research Department of Primary Care and Population Health, University College London, London, UK

3. Applied Research Collaboration Greater Manchester, Division of Population Health, Health Services Research and Primary Care, University of Manchester, Manchester, UK

4. Universidad de Las Palmas de Gran Canaria, La Palmas, Spain

5. Specialist Centre for Kidney Cancer, Royal Free Hospital, London, UK

6. Faculty of Medical Sciences, University College London, London, UK

7. Alliance Manchester Business School, University of Manchester, Manchester, UK

8. North Central London Cancer Alliance, London, UK

9. Patient and public representative, London, UK

10. Patient and public representative, Greater Manchester, UK

11. University College London Hospitals NHS Foundation Trust, London, UK

12. Our Future Health, Manchester, UK

13. Salford Royal NHS Foundation Trust, Salford, UK

14. UCLPartners Academic Health Science Network, London, UK

15. Greater Manchester Cancer and Manchester Academic Health Science Centre, The Christie NHS Foundation Trust, Manchester, UK

16. Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK

Abstract

BackgroundCentralising specialist cancer surgical services is an example of major system change. High-volume centres are recommended to improve specialist cancer surgery care and outcomes.ObjectiveOur aim was to use a mixed-methods approach to evaluate the centralisation of specialist surgery for prostate, bladder, renal and oesophago-gastric cancers in two areas of England [i.e. London Cancer (London, UK), which covers north-central London, north-east London and west Essex, and Greater Manchester Cancer (Manchester, UK), which covers Greater Manchester].DesignStakeholder preferences for centralising specialist cancer surgery were analysed using a discrete choice experiment, surveying cancer patients (n = 206), health-care professionals (n = 111) and the general public (n = 127). Quantitative analysis of impact on care, outcomes and cost-effectiveness used a controlled before-and-after design. Qualitative analysis of implementation and outcomes of change used a multisite case study design, analysing documents (n = 873), interviews (n = 212) and non-participant observations (n = 182). To understand how lessons apply in other contexts, we conducted an online workshop with stakeholders from a range of settings. A theory-based framework was used to synthesise these approaches.ResultsStakeholder preferences– patients, health-care professionals and the public had similar preferences, prioritising reduced risk of complications and death, and better access to specialist teams. Travel time was considered least important.Quantitative analysis (impact of change)– only London Cancer’s centralisations happened soon enough for analysis. These changes were associated with fewer surgeons doing more operations and reduced length of stay [prostate –0.44 (95% confidence interval –0.55 to –0.34) days; bladder –0.563 (95% confidence interval –4.30 to –0.83) days; renal –1.20 (95% confidence interval –1.57 to –0.82) days]. The centralisation meant that renal patients had an increased probability of receiving non-invasive surgery (0.05, 95% confidence interval 0.02 to 0.08). We found no evidence of impact on mortality or re-admissions, possibly because risk was already low pre-centralisation. London Cancer’s prostate, oesophago-gastric and bladder centralisations had medium probabilities (79%, 62% and 49%, respectively) of being cost-effective, and centralising renal services was not cost-effective (12% probability), at the £30,000/quality-adjusted life-year threshold.Qualitative analysis, implementation and outcomes– London Cancer’s provider-led network overcame local resistance by distributing leadership throughout the system. Important facilitators included consistent clinical leadership and transparent governance processes. Greater Manchester Cancer’s change leaders learned from history to deliver the oesophago-gastric centralisation. Greater Manchester Cancer’s urology centralisations were not implemented because of local concerns about the service model and local clinician disengagement. London Cancer’s network continued to develop post implementation. Consistent clinical leadership helped to build shared priorities and collaboration. Information technology difficulties had implications for interorganisational communication and how reliably data follow the patient. London Cancer’s bidding processes and hierarchical service model meant that staff reported feelings of loss and a perceived ‘us and them’ culture.Workshop– our findings resonated with workshop attendees, highlighting issues about change leadership, stakeholder collaboration and implications for future change and evaluation.LimitationsThe discrete choice experiment used a convenience sample, limiting generalisability. Greater Manchester Cancer implementation delays meant that we could study the impact of only London Cancer changes. We could not analyse patient experience, quality of life or functional outcomes that were important to patients (e.g. continence).Future researchFuture research may focus on impact of change on care options offered, patient experience, functional outcomes and long-term sustainability. Studying other approaches to achieving high-volume services would be valuable.Study registrationNational Institute for Health and Care Research (NIHR) Clinical Research Network Portfolio reference 19761.FundingThis project was funded by the NIHR Health and Social Care Delivery Research programme and will be published in full inHealth and Social Care Delivery Research; Vol. 11, No. 2. See the NIHR Journals Library website for further project information.

Funder

Health and Social Care Delivery Research (HSDR) Programme

Publisher

National Institute for Health and Care Research

Subject

Health (social science),Care Planning,Health Policy

Reference220 articles.

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3